Current through September 16, 2024
1. Except as otherwise provided in NAC
441A.240, the director or other
person in charge of a medical laboratory in which a test or examination of any
specimen derived from the human body yields evidence suggesting the presence of
a communicable disease, a causative agent of a communicable disease or an
immune response to a causative agent of a communicable disease shall:
(a) If the medical laboratory is in this
State, report the findings to the health authority having jurisdiction where
the office of the health care provider who ordered the test or examination is
located or to an electronic clearinghouse approved by the health
authority.
(b) If the medical
laboratory performed the test or examination on specimens obtained in this
State or from residents of this State, and the medical laboratory is located
outside of this State, report the findings to the Chief Medical Officer.
The report must be made in the manner provided in NAC
441A.225.
2. The report must include:
(a) The date and result of the test or
examination performed.
(b) The
name, address and, if available, telephone number of the person from whom the
specimen was obtained.
(c) The sex,
age and date of birth of the person from whom the specimen was obtained, if
available.
(d) The name of the
health care provider who ordered the test or examination.
(e) The name and the address or telephone
number of the medical laboratory making the report.
(f) Any other information requested by the
health authority, if available.
3. The director or other person in charge of
the medical laboratory shall also submit microbiologic cultures, subcultures,
culture-independent diagnostic tests or other specimens or clinical material,
if available, to the State Public Health Laboratory or other laboratory
designated by the health authority for diagnosis, confirmation or further
testing if:
(a) Requested by the health
authority;
(b) Requested by the
Chief Medical Officer or a representative thereof for the purpose of
phylogenetic analysis;
(c) The
communicable disease is included on the list of diseases published by the
health authority pursuant to subsection 4 and the health authority has provided
the director or other person in charge of the medical laboratory with a copy of
the list; or
(d) The microbiologic
cultures, subcultures, or other specimens or clinical material consist of:
(1) Isolates of Bordetella
pertussis or Bordetella parapertussis;
(2) Isolates of non-motile and non-hemolytic
Bacillus spp.;
(3)
Isolates of Brucella spp.;
(4) Isolates of Burkholderia
mallei or Burkholderia pseudomallei;
(5) Isolates and positive culture-independent
specimens of Candida auris ;
(6) Isolates of
Campylobacter spp.;
(7) Specimens suspected to contain
Clostridium botulinum;
(8) Isolates of Clostridium
tetani;
(9) Isolates of
Corynebacterium diptheriae ;
(10) Isolates of Coxiella
burnetii;
(11) Isolates of
E. coli O157:H7;
(12) Isolates of Francisella
tularensis;
(13) Isolates
of Haemophilus influenza (invasive only);
(14) Isolates of Legionella
spp.;
(15) Isolates of
Listeria monocytogenes;
(16) Isolates of
Mycobacterium spp.;
(17) Isolates of Neisseria
meningitidis from a sterile site;
(18) Blood smears containing
Plasmodium spp.;
(19) Isolates of Salmonella
spp.;
(20) Isolates of, or broth
positive results for, Shiga toxin-producing Escherichia
coli;
(21) Isolates of
Shigella spp.;
(22) Isolates of Vibrio
spp.;
(23) Isolates of
Vancomycin-intermediate Staphylococcus aureus;
(24) Isolates of Vancomycin-resistant
Staphylococcus aureus;
(25) Isolates of Yersinia
pestis; or
(26) Isolates
of Yersinia spp., other than Yersinia
pestis.
4. The health authority shall annually
publish and post on its Internet website a list of communicable diseases for
which microbiologic cultures, subcultures, culture-independent diagnostic tests
or other specimens or clinical material, if available, must be submitted
pursuant to subsection 3. For each communicable disease included on the list,
the health authority must specify:
(a) The
microbiologic cultures, subcultures, culture-independent diagnostic tests or
other specimens or clinical material to be submitted;
(b) The justification for requiring the
microbiologic cultures, subcultures, cultureindependent diagnostic tests or
other specimens or clinical material to be submitted;
(c) The name of the medical laboratory to
which the microbiologic cultures, subcultures, culture-independent diagnostic
tests or other specimens or clinical material must be submitted; and
(d) The process by which the microbiologic
cultures, subcultures, culture-independent diagnostic tests or other specimens
or clinical material must be submitted.
5. If the director or other person in charge
of the medical laboratory submits a cultureindependent diagnostic test pursuant
to subsection 3, the State Public Health Laboratory must conduct reflex testing
for the purpose of surveillance.
6.
Except as otherwise provided in NAC
441A.240, the director or other
person in charge of a medical laboratory shall report as required by this
section the results of any test of any specimen derived from the human body, if
the test is approved by the Food and Drug Administration of the United States
Department of Health and Human Services, and:
(a) The results of the test confirm the
presence of the human immunodeficiency virus (HIV) or antibodies to the human
immunodeficiency virus (HIV); or
(b) The test was conducted to monitor the
progression of a human immunodeficiency virus (HIV) infection, including,
without limitation, all levels of CD4, human immunodeficiency virus (HIV)
nucleotide sequences or genotype results and both detectable and undetectable
viral loads.
7. With
respect to a test described in subsection 6, if the interpretation of the
laboratory diagnostic testing algorithm is positive, indicating the presence of
infection with the human immunodeficiency virus (HIV), the laboratory must
report to the health authority:
(a) The
overall result or conclusion of the algorithm; and
(b) Results from all such tests, including,
without limitation, negative, nonreactive or intermediate results, that are
performed as part of the testing algorithm, including, without limitation:
(1) Fourth-generation and third-generation
tests for the human immunodeficiency virus (HIV);
(2) Human immunodeficiency virus antibody
differentiation tests (HIV-1/-2); and
(3) Nucleic acid amplification tests (NAT)
for the presence of the human immunodeficiency virus (HIV).
8. The director or other
person in charge of a medical laboratory shall report to the health authority
negative results of any test or examination conducted by the medical laboratory
for hepatitis C or the human immunodeficiency virus (HIV) in the manner
provided in NAC
441A.225. Such a report must
include, without limitation:
(a) The date and
result of the test or examination.
(b) The name, address and, if available,
telephone number of the person from whom the specimen was obtained.
(c) If available, the sex, age and date of
birth of the person from whom the specimen was obtained.
(d) The name of the health care provider who
ordered the test or examination.
(e) The name and address or telephone number
of the medical laboratory.
(f) Any
other information requested by the health authority, if available.
Added to NAC by Bd. of
Health, eff. 1-24-92; A 11-1-95; R087-08, 1-13-2011; A by
R121-14,
eff. 10/27/2015; A by
R187-18A,
eff. 6/12/2019; A by
R148-22A,
eff. 7/31/2023
NRS 439.200,
441A.120
